An investigation for investors in Shire PLC (ADR) (NASDAQ:SHPG) shares over potential securities laws violations by Shire PLC was announced.

San Diego, CA -- (SBWire) -- 06/19/2017 --An investigation was announced for investors of Shire PLC over potential securities laws violations by Shire PLC and certain of its directors and officers.

Investors who purchased shares of Shire PLC (ADR) (NASDAQ:SHPG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Shire PLC (ADR) (NASDAQ:SHPG) concerning whether a series of statements by Shire PLC regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 7, 2017, Shire PLC revealed that it has stopped a U.S. study of Alpha-1 Antitrypsin (G1-ATT IV), its graft-versus-host disease treatment, and will hand over its Investigational New Drug application to Kamada Ltd. for additional testing Shares of Shire PLC (ADR) (NASDAQ:SHPG) closed on June 15, 2017 at $164.72 per share.

Those who purchased shares of Shire PLC (ADR) (NASDAQ:SHPG) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com